{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "agomelatine (valdoxan)",
      "deficit and \u00absecondary\u00bb negative symptoms",
      "postschizophrenic depression",
      "psychopathological structure"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [
    {
      "AbstractText": [
        "\u0426\u0435\u043b\u044c \u0438\u0441\u0441\u043b\u0435\u0434\u043e\u0432\u0430\u043d\u0438\u044f. \u041e\u043f\u0440\u0435\u0434\u0435\u043b\u0438\u0442\u044c \u043e\u0441\u043e\u0431\u0435\u043d\u043d\u043e\u0441\u0442\u0438 \u0442\u0435\u0440\u0430\u043f\u0435\u0432\u0442\u0438\u0447\u0435\u0441\u043a\u043e\u0433\u043e \u0434\u0435\u0439\u0441\u0442\u0432\u0438\u044f \u0430\u0433\u043e\u043c\u0435\u043b\u0430\u0442\u0438\u043d\u0430 (\u0432\u0430\u043b\u044c\u0434\u043e\u043a\u0441\u0430\u043d\u0430) \u043d\u0430 \u043f\u043e\u0441\u0442\u0448\u0438\u0437\u043e\u0444\u0440\u0435\u043d\u0438\u0447\u0435\u0441\u043a\u0443\u044e \u0434\u0435\u043f\u0440\u0435\u0441\u0441\u0438\u044e (\u041f\u0428\u0414) \u0441 \u0443\u0447\u0435\u0442\u043e\u043c \u0435\u0435 \u043f\u0441\u0438\u0445\u043e\u043f\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u0447\u0435\u0441\u043a\u043e\u0439 \u0441\u0442\u0440\u0443\u043a\u0442\u0443\u0440\u044b. \u041c\u0430\u0442\u0435\u0440\u0438\u0430\u043b \u0438 \u043c\u0435\u0442\u043e\u0434\u044b. \u041a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0438\u043c \u0438 \u043f\u0441\u0438\u0445\u043e\u043c\u0435\u0442\u0440\u0438\u0447\u0435\u0441\u043a\u0438\u043c \u043c\u0435\u0442\u043e\u0434\u043e\u043c \u043e\u0431\u0441\u043b\u0435\u0434\u043e\u0432\u0430\u043d\u044b 33 \u0431\u043e\u043b\u044c\u043d\u044b\u0445 \u043e\u0431\u043e\u0435\u0433\u043e \u043f\u043e\u043b\u0430 (\u0441\u0440\u0435\u0434\u043d\u0438\u0439 \u0432\u043e\u0437\u0440\u0430\u0441\u0442 32,1 \u0433\u043e\u0434\u0430) \u0441 \u043a\u0430\u0440\u0442\u0438\u043d\u043e\u0439 \u041f\u0428\u0410 (F20.4 \u043f\u043e \u041c\u041a\u0411-10) \u043f\u0440\u0438 \u043f\u0440\u0438\u0441\u0442\u0443\u043f\u043e\u043e\u0431\u0440\u0430\u0437\u043d\u043e\u0439 \u0448\u0438\u0437\u043e\u0444\u0440\u0435\u043d\u0438\u0438. \u0418\u0441\u043f\u043e\u043b\u044c\u0437\u043e\u0432\u0430\u043b\u0438\u0441\u044c \u0448\u043a\u0430\u043b\u044b HAM-D-17, PANSS \u0438 CGI-S. \u0412\u0441\u0435 \u0431\u043e\u043b\u044c\u043d\u044b\u0435 \u0431\u044b\u043b\u0438 \u0440\u0430\u0437\u0434\u0435\u043b\u0435\u043d\u044b \u043d\u0430 \u0433\u0440\u0443\u043f\u043f\u044b \u0432 \u0437\u0430\u0432\u0438\u0441\u0438\u043c\u043e\u0441\u0442\u0438 \u043e\u0442 \u0441\u0442\u0435\u043f\u0435\u043d\u0438 \u0442\u044f\u0436\u0435\u0441\u0442\u0438: \u043b\u0435\u0433\u043a\u0438\u0435, \u0443\u043c\u0435\u0440\u0435\u043d\u043d\u044b\u0435 \u0438 \u0442\u044f\u0436\u0435\u043b\u044b\u0435 \u0434\u0435\u043f\u0440\u0435\u0441\u0441\u0438\u0438. \u0412\u0430\u043b\u044c\u0434\u043e\u043a\u0441\u0430\u043d \u043d\u0430\u0437\u043d\u0430\u0447\u0430\u043b\u0441\u044f \u043f\u043e 25-50 \u043c\u0433/\u0441\u0443\u0442 \u0438 \u0442\u0435\u0447\u0435\u043d\u0438\u0435 28 \u0441\u0443\u0442 \u043d\u0430 \u0444\u043e\u043d\u0435 \u043f\u0440\u0435\u0434\u0448\u0435\u0441\u0442\u0432\u0443\u044e\u0449\u0435\u0439 \u043d\u0435\u0439\u0440\u043e\u043b\u0435\u043f\u0442\u0438\u0447\u0435\u0441\u043a\u043e\u0439 \u0442\u0435\u0440\u0430\u043f\u0438\u0438 \u0432 \u043f\u043e\u0434\u0434\u0435\u0440\u0436\u0438\u0432\u0430\u044e\u0449\u0438\u0445 \u0434\u043e\u0437\u0430\u0445. \u041e\u0446\u0435\u043d\u043a\u0430 \u044d\u0444\u0444\u0435\u043a\u0442\u0438\u0432\u043d\u043e\u0441\u0442\u0438 \u043b\u0435\u0447\u0435\u043d\u0438\u044f \u043f\u0440\u043e\u0432\u043e\u0434\u0438\u043b\u0430\u0441\u044c \u043f\u043e \u0440\u0435\u0434\u0443\u043a\u0446\u0438\u0438 (\u0432 \u043f\u0440\u043e\u0446\u0435\u043d\u0442\u0430\u0445) \u043f\u043e\u043a\u0430\u0437\u0430\u0442\u0435\u043b\u0435\u0439 \u0441\u0440\u0435\u0434\u043d\u0435\u0433\u043e \u0441\u0443\u043c\u043c\u0430\u0440\u043d\u043e\u0433\u043e \u0431\u0430\u043b\u043b\u0430 (\u0421\u0421\u0411) \u0432 \u0434\u0438\u043d\u0430\u043c\u0438\u043a\u0435. \u0420\u0435\u0437\u0443\u043b\u044c\u0442\u0430\u0442\u044b. \u041f\u043e\u043a\u0430\u0437\u0430\u0442\u0435\u043b\u044c \u0442\u0435\u0440\u0430\u043f\u0435\u0432\u0442\u0438\u0447\u0435\u0441\u043a\u043e\u0433\u043e \u044d\u0444\u0444\u0435\u043a\u0442\u0430 \u0432\u0430\u043b\u044c\u0434\u043e\u043a\u0441\u0430\u043d\u0430 \u0443\u0441\u0442\u0430\u043d\u043e\u0432\u043b\u0435\u043d \u043d\u0430 \u0443\u0440\u043e\u0432\u043d\u0435 \u0437\u043d\u0430\u0447\u0438\u043c\u043e\u0433\u043e \u0438 \u0441\u043e\u0441\u0442\u0430\u0432\u0438\u043b 73,8% \u0440\u0435\u0434\u0443\u043a\u0446\u0438\u0438 \u0440\u0430\u0441\u0441\u0442\u0440\u043e\u0439\u0441\u0442\u0432 \u043f\u043e \u0448\u043a\u0430\u043b\u0435 PANSS \u043f\u0440\u0438 \u0431\u044b\u0441\u0442\u0440\u043e\u043c \u0442\u0435\u043c\u043f\u0435 \u0444\u043e\u0440\u043c\u0438\u0440\u043e\u0432\u0430\u043d\u0438\u044f \u043b\u0435\u043a\u0430\u0440\u0441\u0442\u0432\u0435\u043d\u043d\u043e\u0433\u043e \u043e\u0442\u0432\u0435\u0442\u0430 \u0432 \u043f\u0435\u0440\u0438\u043e\u0434 \u043e\u0442 7 \u0434\u043e 21 \u0441\u0443\u0442 \u043b\u0435\u0447\u0435\u043d\u0438\u044f. \u0422\u0435\u0440\u0430\u043f\u0435\u0432\u0442\u0438\u0447\u0435\u0441\u043a\u043e\u0435 \u0432\u043e\u0437\u0434\u0435\u0439\u0441\u0442\u0432\u0438\u0435 \u0432\u0430\u043b\u044c\u0434\u043e\u043a\u0441\u0430\u043d\u0430 \u043d\u0430 \u043e\u0442\u0434\u0435\u043b\u044c\u043d\u044b\u0435 \u043a\u043e\u043c\u043f\u043e\u043d\u0435\u043d\u0442\u044b \u041f\u0428\u0414 \u0431\u044b\u043b\u043e \u043d\u0435\u0440\u0430\u0432\u043d\u043e\u043c\u0435\u0440\u043d\u044b\u043c. \u041e\u0434\u0438\u043d\u0430\u043a\u043e\u0432\u043e \u0432\u044b\u0441\u043e\u043a\u0438\u043c \u0431\u044b\u043b \u043f\u043e\u043a\u0430\u0437\u0430\u0442\u0435\u043b\u044c \u0440\u0435\u0434\u0443\u043a\u0446\u0438\u0438 \u0441\u043e\u0431\u0441\u0442\u0432\u0435\u043d\u043d\u043e \u0434\u0435\u043f\u0440\u0435\u0441\u0441\u0438\u0432\u043d\u044b\u0445 \u0440\u0430\u0441\u0441\u0442\u0440\u043e\u0439\u0441\u0442\u0432 \u0432 \u043a\u0430\u0440\u0442\u0438\u043d\u0435 \u0442\u0438\u043c\u0438\u0447\u0435\u0441\u043a\u043e\u0433\u043e \u043a\u043e\u043c\u043f\u043e\u043d\u0435\u043d\u0442\u0430, \u043a\u043e\u0442\u043e\u0440\u044b\u0439 \u0441\u043e\u0441\u0442\u0430\u0432\u0438\u043b \u043f\u043e \u043e\u0446\u0435\u043d\u043a\u0435 \u0448\u043a\u0430\u043b\u044b HA\u041c-D-17 \u0438 \u043f\u043e\u0434\u0448\u043a\u0430\u043b\u044b G PANSS 78,4 \u0438 78,2% \u0441\u043e\u043e\u0442\u0432\u0435\u0442\u0441\u0442\u0432\u0435\u043d\u043d\u043e. \u0422\u0435\u0440\u0430\u043f\u0435\u0432\u0442\u0438\u0447\u0435\u0441\u043a\u0430\u044f \u0440\u0435\u0434\u0443\u043a\u0446\u0438\u044f \u043d\u0435\u0433\u0430\u0442\u0438\u0432\u043d\u044b\u0445 \u0440\u0430\u0441\u0441\u0442\u0440\u043e\u0439\u0441\u0442\u0432 \u043f\u043e \u043f\u043e\u0434\u0448\u043a\u0430\u043b\u0435 N PANSS \u0431\u044b\u043b\u0430 \u043d\u0430\u0438\u043c\u0435\u043d\u044c\u0448\u0435\u0439 (\u043d\u0430 \u0443\u0440\u043e\u0432\u043d\u0435 \u0445\u043e\u0440\u043e\u0448\u0435\u0433\u043e \u044d\u0444\u0444\u0435\u043a\u0442\u0430) \u0438 \u0441\u043e\u0441\u0442\u0430\u0432\u0438\u043b\u0430 53,6%. \u0412 27,3% \u0441\u043b\u0443\u0447\u0430\u0435\u0432 \u043d\u0435\u0433\u0430\u0442\u0438\u0432\u043d\u044b\u0435 \u0440\u0430\u0441\u0441\u0442\u0440\u043e\u0439\u0441\u0442\u0432\u0430 \u0431\u044b\u043b\u0438 \u043d\u0435\u043e\u0431\u0440\u0430\u0442\u0438\u043c\u044b \u0438 \u0440\u0430\u0441\u0446\u0435\u043d\u0438\u0432\u0430\u043b\u0438\u0441\u044c \u043a\u0430\u043a \u0434\u0435\u0444\u0438\u0446\u0438\u0442\u0430\u0440\u043d\u044b\u0435, \u0443 72,7% \u0431\u043e\u043b\u044c\u043d\u044b\u0445 \u043e\u043d\u0438 \u0434\u0438\u0430\u0433\u043d\u043e\u0441\u0442\u0438\u0440\u043e\u0432\u0430\u043b\u0438\u0441\u044c \u043a\u0430\u043a \u0432\u0442\u043e\u0440\u0438\u0447\u043d\u044b\u0435 \u043d\u0435\u0433\u0430\u0442\u0438\u0432\u043d\u044b\u0435 \u0432 \u043a\u0430\u0440\u0442\u0438\u043d\u0435 \u0430\u0442\u0438\u043f\u0438\u0447\u043d\u043e\u0439 \u0434\u0435\u043f\u0440\u0435\u0441\u0441\u0438\u0438. \u0412 \u0433\u0440\u0443\u043f\u043f\u0430\u0445 \u043f\u0430\u0446\u0438\u0435\u043d\u0442\u043e\u0432 \u0441 \u043b\u0435\u0433\u043a\u043e\u0439, \u0443\u043c\u0435\u0440\u0435\u043d\u043d\u043e\u0439 \u0438 \u0442\u044f\u0436\u0435\u043b\u043e\u0439 \u0441\u0442\u0435\u043f\u0435\u043d\u044c\u044e \u0434\u0435\u043f\u0440\u0435\u0441\u0441\u0438\u0438 \u043f\u043e\u043a\u0430\u0437\u0430\u0442\u0435\u043b\u0438 \u0440\u0435\u0434\u0443\u043a\u0446\u0438\u0438 \u043d\u0435\u0433\u0430\u0442\u0438\u0432\u043d\u044b\u0445 \u0440\u0430\u0441\u0441\u0442\u0440\u043e\u0439\u0441\u0442\u0432 \u0431\u044b\u043b\u0438 62,4; 44,2 \u0438 60,8% \u0441\u043e\u043e\u0442\u0432\u0435\u0442\u0441\u0442\u0432\u0435\u043d\u043d\u043e, \u0441\u0438\u043c\u043f\u0442\u043e\u043c\u043e\u0432 \u043f\u043e \u0448\u043a\u0430\u043b\u0435 PANSS - 81,5; 66,1 \u0438 78,6% \u0441\u043e\u043e\u0442\u0432\u0435\u0442\u0441\u0442\u0432\u0435\u043d\u043d\u043e, \u0442.\u0435. \u043d\u0430\u043f\u0440\u044f\u043c\u0443\u044e \u043d\u0435 \u0441\u043e\u043e\u0442\u0432\u0435\u0442\u0441\u0442\u0432\u043e\u0432\u0430\u043b\u0438 \u0441\u0442\u0435\u043f\u0435\u043d\u0438 \u0442\u044f\u0436\u0435\u0441\u0442\u0438 \u0434\u0435\u043f\u0440\u0435\u0441\u0441\u0438\u0432\u043d\u044b\u0445 \u0440\u0430\u0441\u0441\u0442\u0440\u043e\u0439\u0441\u0442\u0432. \u0417\u0430\u043a\u043b\u044e\u0447\u0435\u043d\u0438\u0435. \u0410\u0433\u043e\u043c\u0435\u043b\u0430\u0442\u0438\u043d (\u0432\u0430\u043b\u044c\u0434\u043e\u043a\u0441\u0430\u043d) \u044f\u0432\u043b\u044f\u0435\u0442\u0441\u044f \u044d\u0444\u0444\u0435\u043a\u0442\u0438\u0432\u043d\u044b\u043c \u0441\u0440\u0435\u0434\u0441\u0442\u0432\u043e\u043c \u043e\u043f\u0442\u0438\u043c\u0438\u0437\u0430\u0446\u0438\u0438 \u043c\u0435\u0442\u043e\u0434\u043e\u0432 \u043b\u0435\u0447\u0435\u043d\u0438\u044f \u041f\u0428\u0414, \u043e\u0431\u0435\u0441\u043f\u0435\u0447\u0438\u0432\u0430\u044f \u0442\u0435\u0440\u0430\u043f\u0435\u0432\u0442\u0438\u0447\u0435\u0441\u043a\u0438\u0439 \u044d\u0444\u0444\u0435\u043a\u0442 \u043d\u0430 \u0443\u0440\u043e\u0432\u043d\u0435 \u0437\u043d\u0430\u0447\u0438\u043c\u043e\u0433\u043e \u0438\u043b\u0438 \u043f\u043e\u043b\u043d\u043e\u0439 \u0440\u0435\u0434\u0443\u043a\u0446\u0438\u0438 \u0441\u0438\u043c\u043f\u0442\u043e\u043c\u043e\u0432. \u041a\u0430\u0447\u0435\u0441\u0442\u0432\u043e \u0438 \u0442\u0435\u043c\u043f \u0444\u043e\u0440\u043c\u0438\u0440\u043e\u0432\u0430\u043d\u0438\u044f \u043b\u0435\u043a\u0430\u0440\u0441\u0442\u0432\u0435\u043d\u043d\u043e\u0433\u043e \u043e\u0442\u0432\u0435\u0442\u0430 \u0432 \u0434\u0438\u043d\u0430\u043c\u0438\u043a\u0435 \u043a\u0443\u0440\u0441\u043e\u0432\u043e\u0433\u043e \u043b\u0435\u0447\u0435\u043d\u0438\u044f \u043e\u043f\u0440\u0435\u0434\u0435\u043b\u044f\u044e\u0442\u0441\u044f \u043d\u0435 \u0442\u044f\u0436\u0435\u0441\u0442\u044c\u044e \u0441\u043e\u0431\u0441\u0442\u0432\u0435\u043d\u043d\u043e \u0434\u0435\u043f\u0440\u0435\u0441\u0441\u0438\u0432\u043d\u044b\u0445 \u0440\u0430\u0441\u0441\u0442\u0440\u043e\u0439\u0441\u0442\u0432 \u0432 \u0441\u0442\u0440\u0443\u043a\u0442\u0443\u0440\u0435 \u041f\u0428\u0414, \u0430 \u0441\u043e\u043e\u0442\u043d\u043e\u0448\u0435\u043d\u0438\u0435\u043c \u0434\u0435\u0444\u0438\u0446\u0438\u0442\u0430\u0440\u043d\u044b\u0445 \u0438 \u0432\u0442\u043e\u0440\u0438\u0447\u043d\u044b\u0445 \u043d\u0435\u0433\u0430\u0442\u0438\u0432\u043d\u044b\u0445 \u0441\u0438\u043c\u043f\u0442\u043e\u043c\u043e\u0432, \u043e\u0442\u0440\u0430\u0436\u0430\u044e\u0449\u0438\u0445 \u0441\u0442\u0435\u043f\u0435\u043d\u044c \u043f\u0440\u043e\u0433\u0440\u0435\u0434\u0438\u0435\u043d\u0442\u043d\u043e\u0441\u0442\u0438 \u043e\u0441\u043d\u043e\u0432\u043d\u043e\u0433\u043e \u0437\u0430\u0431\u043e\u043b\u0435\u0432\u0430\u043d\u0438\u044f."
      ]
    }
  ],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "29652308",
  "DateCompleted": {
    "Year": "2019",
    "Month": "06",
    "Day": "10"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "03",
    "Day": "28"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "rus"
    ],
    "ELocationID": [
      "10.17116/jnevro20181183159-69"
    ],
    "Journal": {
      "ISSN": "1997-7298",
      "JournalIssue": {
        "Volume": "118",
        "Issue": "3",
        "PubDate": {
          "Year": "2018"
        }
      },
      "Title": "Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova",
      "ISOAbbreviation": "Zh Nevrol Psikhiatr Im S S Korsakova"
    },
    "ArticleTitle": "[Clinical-psychopathological aspects of therapeutic effects of agomelatine (valdoxan) and its place in perfection of methods of therapy of postschizophrenic depressive disorders].",
    "Pagination": {
      "StartPage": "59",
      "EndPage": "69",
      "MedlinePgn": "59-69"
    },
    "Abstract": {
      "AbstractText": [
        "To determine a therapeutic effect of agomelatine (valdoxan) on post-schizophrenic depression (PSD), taking into account its psychopathological structure.",
        "A total of 33 patients of both sexes (average age was 32.1 yrs) with symptoms of post-schizophrenic depression (F20.4 according to ICD-10) were examined by using clinical and psychometric methods in the dynamics of shift-like schizophrenia. HAMD-17, PANSS and CGI-S scales were applied. All the patients were subdivided into groups: mild, moderate and severe depressions. Valdoxan was used at a dose of 25-50 mg/day for 28 days along with preceding antipsychotic therapy at maintenance doses. Evaluation of the efficacy of treatment was carried out according to percentage reduction of average total score (ATS) in dynamics.",
        "A significant effect of valdoxan, with 73.5% of PANSS score reduction and quicker response to treatment, was identified. Therapeutic effect of valdoxan on separate components of PSD was uneven. The decrease of depressive disorders per se assessed by HA\u041cD-17 and PANSS G-subscale was equally high (78.4 and 78.2%, respectively). Therapeutic reduction of negative disorders according to PANSS N-subscale was the lowest, at the level of 'good' effect (53.6%). In 27.3%, negative disorders were irreversible and were assessed as schizophrenic defect; in 72.7% of patients they were diagnosed as 'secondary' negative symptoms in atypical depression. In the subgroups of mild, moderate, and severe depression, the reduction of negative disorders was 62.4; 44.2 and 60.8%, respectively, and that of total PANSS score were 81.5; 66.1, and 78.6%, i.e. there was no correlation between these variables.",
        "Agomelatin (valdoxan) is an effective medication for optimization of methods of PSD treatment, providing the therapeutic effect at the level of significant or complete reduction of symptoms. The quality (depth) and rate of formation of response in the dynamics of course treatment are determined not by the severity of depressive disorders in PSD structure, but by the ratio between negative (deficit) symptoms and 'secondary' symptoms, reflecting the degree of progression of the main disease."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Mental Health Research Centre, Moscow, Russia."
          }
        ],
        "LastName": "Panteleyeva",
        "ForeName": "G P",
        "Initials": "GP"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Mental Health Research Centre, Moscow, Russia."
          }
        ],
        "LastName": "Abramova",
        "ForeName": "L I",
        "Initials": "LI"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Mental Health Research Centre, Moscow, Russia."
          }
        ],
        "LastName": "Novozhenova",
        "ForeName": "T E",
        "Initials": "TE"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Mental Health Research Centre, Moscow, Russia."
          }
        ],
        "LastName": "Subbotskaya",
        "ForeName": "N V",
        "Initials": "NV"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Mental Health Research Centre, Moscow, Russia."
          }
        ],
        "LastName": "Tikhonov",
        "ForeName": "D V",
        "Initials": "DV"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Mental Health Research Centre, Moscow, Russia."
          }
        ],
        "LastName": "Yumatova",
        "ForeName": "P E",
        "Initials": "PE"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Mental Health Research Centre, Moscow, Russia."
          }
        ],
        "LastName": "Nikiforova",
        "ForeName": "I Yu",
        "Initials": "IY"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ],
    "VernacularTitle": "Kliniko-psikhopatologicheskie aspekty osobennoste\u012d terapevticheskogo de\u012dstviia agomelatina (val'doksana) i ego mesto v usovershenstvovanii metodov terapii postshizofrenicheskikh depressi\u012d."
  },
  "MedlineJournalInfo": {
    "Country": "Russia (Federation)",
    "MedlineTA": "Zh Nevrol Psikhiatr Im S S Korsakova",
    "NlmUniqueID": "9712194",
    "ISSNLinking": "1997-7298"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Acetamides"
    },
    {
      "RegistryNumber": "137R1N49AD",
      "NameOfSubstance": "agomelatine"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Acetamides"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Depression"
    },
    {
      "QualifierName": [
        "drug therapy"
      ],
      "DescriptorName": "Depressive Disorder"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Psychiatric Status Rating Scales"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Psychopathology"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Schizophrenia"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Treatment Outcome"
    }
  ]
}